A groundbreaking Phase 1 clinical trial has revealed that a single dose of an experimental gene-editing therapy can significantly lower cholesterol and triglyceride levels,...
UPDATE: Crispr Therapeutics (CRSP) is making headlines as its stock rockets up by 65% year-to-date through September 30, 2025. However, despite this impressive surge,...